- Home
- NUKK vs RNXT Comparison
NUKK vs RNXT Comparison
Compare NUKK & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- RNXT
- Stock Information
- Founded
- NUKK 2013
- RNXT 2012
- Country
- NUKK United States
- RNXT United States
- Employees
- NUKK N/A
- RNXT N/A
- Industry
- NUKK Blank Checks
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- RNXT Health Care
- Exchange
- NUKK Nasdaq
- RNXT Nasdaq
- Market Cap
- NUKK 52.1M
- RNXT 44.6M
- IPO Year
- NUKK N/A
- RNXT 2021
- Fundamental
- Price
- NUKK $8.05
- RNXT $1.29
- Analyst Decision
- NUKK
- RNXT Strong Buy
- Analyst Count
- NUKK 0
- RNXT 2
- Target Price
- NUKK N/A
- RNXT $7.25
- AVG Volume (30 Days)
- NUKK 237.7K
- RNXT 150.4K
- Earning Date
- NUKK 09-10-2025
- RNXT 08-14-2025
- Dividend Yield
- NUKK N/A
- RNXT N/A
- EPS Growth
- NUKK N/A
- RNXT N/A
- EPS
- NUKK N/A
- RNXT N/A
- Revenue
- NUKK N/A
- RNXT $240,000.00
- Revenue This Year
- NUKK N/A
- RNXT $3,104.65
- Revenue Next Year
- NUKK N/A
- RNXT $301.89
- P/E Ratio
- NUKK N/A
- RNXT N/A
- Revenue Growth
- NUKK N/A
- RNXT N/A
- 52 Week Low
- NUKK $1.30
- RNXT $0.75
- 52 Week High
- NUKK $78.32
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- NUKK 33.66
- RNXT 50.51
- Support Level
- NUKK $7.80
- RNXT $1.27
- Resistance Level
- NUKK $8.43
- RNXT $1.40
- Average True Range (ATR)
- NUKK 0.75
- RNXT 0.06
- MACD
- NUKK -0.06
- RNXT -0.01
- Stochastic Oscillator
- NUKK 16.41
- RNXT 40.59
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.